Head-to-head record between Zymergen (ZY) and rivals

0

Zymergen (NASDAQ:ZYGet a rating) is one of 40 publicly traded companies in the “commercial physical research” sector, but how does it compare to its peers? We will compare Zymergen to related companies based on its earnings strength, dividends, analyst recommendations, valuation, profitability, institutional ownership and risk.

Profitability

This chart compares the net margins, return on equity, and return on assets of Zymergen and its peers.

Net margins Return on equity return on assets
Zymergen -2,160.81% -213.99% -64.50%
Zymergen competitors -255.16% -16.00% -2.18%

Institutional and Insider Ownership

48.8% of Zymergen shares are held by institutional investors. By comparison, 56.5% of the shares of all “commercial physical research” companies are held by institutional investors. 10.6% of the shares of all “commercial physical research” companies are held by insiders of the company. Strong institutional ownership indicates that large money managers, endowments, and hedge funds believe a company is poised for long-term growth.

Valuation and benefits

This table compares the revenue, earnings per share (EPS), and valuation of Zymergen and its peers.

Gross revenue Net revenue Price/earnings ratio
Zymergen $16.74 million -$361.79 million -0.19
Zymergen competitors $2.79 billion $101.13 million 21.51

Zymergen peers have higher revenue and profit than Zymergen. Zymergen trades at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Zymergen and its peers, as reported by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Zymergen 3 5 0 0 1.63
Zymergen competitors 100 745 1293 30 2.58

Zymergen currently has a consensus target price of $6.75, indicating a potential upside of 279.21%. As a group, the “Commercial Physical Research” companies have an upside potential of 31.88%. Given Zymergen’s likely higher upside, analysts clearly believe Zymergen is more favorable than its peers.

Summary

Zymergen’s peers beat Zymergen on 11 of the 12 factors compared.

About Zymergen (Get a rating)

Zymergen Inc. designs, develops and markets microbes, molecules and materials. It offers an automation solution including reconfigurable automation carts, modular hardware building blocks that enable the assembly of custom work cells for a lab’s particular needs; and automation control software, cloud-based software used to control embedded automation systems. It serves electronics, packaging, healthcare, agriculture and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.



Get news and reviews for Zymergen Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Zymergen and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

About Author

Comments are closed.